Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories emerging Markets Total Company Sales Growth Excl. FX (%) (%)
Form 10-K MD&A Overview ('Sales in emerging markets, which represent 37 percent of total company sales')
Latest, FY2025
5.1%
Period ended Dec 31, 2025
Change on a year earlier
-3.1 pts
8.2% in FY2024
History
2 years
Since FY2024
Sources
1
SEC Filing (0001628280-26-010185)
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emerging Markets Total Company Sales Growth Excl. FX (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5.1% | -3.1 pts | SEC Filing (0001628280-26-010185) ↗ |
| FY2024 | Dec 31, 2024 | 8.2% | – | SEC Filing (0001628280-26-010185) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Emerging Markets Total Company Sales Growth Excl. FX (%) (%), annual FY2024–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/tot-em-yoy-ex-fx
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.